Keryx Biopharmaceuticals Inc fka KERX

[H2R]

The Commercial Side After Approval

Let's now discuss the leverage behind our launch. The second indication leverages our existing capabilities. It leverages the same access and reimbursement and unlike typical new product launches where access and reimbursement must first be established to turn product demand in to filled prescriptions.

With this new indication, we hit the ground running. It leverages our same target nephrologists who treat dialysis patients for hyperphosphatemia, and also diagnose and treat CKD patients for iron deficiency anemia. And it leverages our same field-based teams.

Over the past nearly three years, our 95 sales specialists has developed relationships with these physicians and thanks to their efforts. Today brand awareness of Auryxia is high in clinical familiarity and experience with the Auryxia is growing. We will leverage all of this as we promote Auryxia in its new indication for the treatment of iron deficiency anemia

That matches the thoughts I had on the commercial side if approved a few days ago:

For the current indication and the potential extension, the sales force is trained, in place, with contacts, manufacturing is set, if the extension is granted, everything is in place to get things moving right away. And it will comfort the current indication too.

Even though it was a terrible day for the PPS, the medium term looks good to me.